Stocks / NASDAQ / Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

Our Opinion

Cleveland BioLabs, Inc. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

Cleveland BioLabs Entolimod (CBLB502) Biodefense product profile

“The efficacy of entolimod as a radiation countermeasure has been assessed in animal models. These studies demonstrate that a single administration of entolimod given either before or after lethal total body irradiation leads to a significant improvement in animal survival.”

Company Description

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company, with a focus on oncology and acute radiation syndrome drug development. It is engaged in the research, development and commercialization of products that have the potential to treat cancer which reduces death from total body irradiation and counteract the toxic effects of radio and chemotherapies for oncology patients. The company has designed two oppositely-directed general therapeutic concepts: temporary and reversible suppression of apoptosis in normal cells to protect healthy tissues from stress-induced damage using compounds categorized as Protectans; and reactivation of apoptosis in tumor cells to eliminate cancer using compounds categorized as Curaxins. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Buffalo, NY. [Source: MarketWatch]

Company Website: